Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aligos Therapeutics Inc (NQ: ALGS )

1.320 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 17, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.320
Bid (Size) 1.130 (5)
Ask (Size) 1.860 (20)
Prev. Close 1.320
Today's Range 1.320 - 1.320
52wk Range 0.8401 - 2.990
Shares Outstanding 42,922,980
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Aligos Therapeutics Earnings Perspective: Return On Capital Employed
 
Via Benzinga
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results
From Aligos Therapeutics
Via Globe NewsWire

Performance

YTD
+40.43%
+40.43%
1 Month
-22.35%
-22.35%
3 Month
+30.69%
+30.69%
6 Month
+13.79%
+13.79%
1 Year
-53.68%
-53.68%

More News

Read More
A Preview Of Aligos Therapeutics's Earnings
Via Benzinga
Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Aligos Therapeutics
Via Globe NewsWire
Aligos Reprioritizes Pipeline With Focus On NASH, COVID Programs, Cuts Another 10% Of Its Workforce
Via Benzinga
Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024
From Aligos Therapeutics
Via Globe NewsWire
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
From Aligos Therapeutics
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
Via Benzinga
Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART Meeting
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver Meeting® 2022
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022
From Aligos Therapeutics
Via Globe NewsWire
SVB Leerink Maintains Market Perform Rating for Aligos Therapeutics: Here's What You Need To Know
Via Benzinga
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics to Announce Third Quarter Results November 2, 2022
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755
From Aligos Therapeutics
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.